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1  | INTRODUC TION
Haematopoietic stem cell transplantation (HSCT) is a treatment used 
for patients with life‐threatening diseases and disorders of the hae‐
matopoietic system. HSCT was found to be a curative treatment for 
some end‐stage acute leukaemia patients over 60 years ago. The 
number of HSCTs increased in recent years, and the milestone of 
1 million HSCTs was reached in 2012.1‐3
Allogeneic HSCT involves an intensive conditioning regimen, that 
includes high‐dose chemotherapy or reduced intensity therapy and, 
possibly, total body irritation (TBI). The aim of this regimen is the erad‐
ication of haematopoietic stem cells and immune system suppression. 
Haematopoietic multipotent stem cells are collected from a donor, 
and the cells are infused to re‐establish haematopoietic functions.1,3,4 
Subsequent to improvements made in the transplantation procedures 
in terms of human leucocyte antigen‐matching, the control of graft vs 
host reactions and the control of infectious complications, the number 
of long‐term survivors has been constantly increasing.5 Nevertheless, 
allogeneic HSCT remains associated with considerable acute and 
long‐term comorbidities that also affect oral health.6‐8
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Objectives: The purpose of this study was to compare the prevalence of common 
oral diseases between allogeneic haematopoietic stem cell transplantation (HSCT) 
recipients and healthy controls.
Materials and methods: A total of 143 adult allogeneic HSCT recipients who were 








were poorer in the HSCT recipients pre‐HSCT compared to controls (all P‐values 
<0.05). No statistically significant differences in the measures of current or previous 
periodontitis were observed.
Conclusions: Stimulated saliva flow rate was low and caries was common in HSCT 
recipients prior to HSCT. Efficient preventive strategies are important in order to 
maintain the oral health of these patients.
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Several studies investigated the associations of poor oral health 
with various systemic diseases and cancer development.9‐12	 Poor	
oral health, especially periodontitis, may be associated with certain 
cancers in different tissues, including those of the mouth, pancreas, 
colorectum and lungs.9,11,12 Studies also suggested a relationship be‐
tween periodontitis and overall cancer mortality.13,14 The evidence of 
associations between oral diseases and haematological malignancies 
is very limited. One study observed that, periodontitis was associated 
with non‐Hodgkin’s lymphoma.15 Another study found an association 
between periodontitis and haematological cancers in men.14
Similar to the studies on the associations between oral diseases 
and haematological malignancies, descriptive studies focused on 
the oral health of patients with disorders of the haematopoietic 
system and/or upcoming HSCT are also scarce. The vast majority 
of studies on HSCT recipients have focused on post‐HSCT symp‐
toms	related	to	GvHD,	mucositis	and	hyposalivation.	We	have	also	
participated in these studies and showed that HSCT recipients 
suffer from hyposalivation, especially 6 months after transplanta‐
tion, and even years post‐HSCT.6,7,16 Hyposalivation is a known 
risk factor for oral diseases and may predispose patients to caries 
in particular.17 In line with this assumption, there is evidence sug‐
gesting poor oral health and high dental treatment needs of HSCT 
recipients pre‐HSCT.18‐20 Another very recent study, with a limited 
number of subjects, observed that patients with newly diagnosed 
acute leukaemia already have poorer oral health, in terms of caries 
and periodontitis, prior to any treatments compared with healthy 
controls.21
The	current	study	examined	the	oral	health	of	allogeneic	HSCT	
recipients pre‐HSCT. The hypothesis was that allogeneic HSCT 
recipients have poorer oral health than healthy controls prior to 
transplantation.
2  | PATIENTS AND METHODS
The Ethikkommision Nordwest‐ und Zentralschweiz (EKNZ), 
Switzerland approved this study (Ref. Nr EKNZ:311‐10) which was 
performed	in	accordance	with	the	Declaration	of	Helsinki.
Adult allogeneic HSCT recipients who were treated in the 
Department	of	Hematology,	University	Hospital	Basel,	Switzerland,	
for haematological malignancies between 2008 and 2016, with 
complete medical and oral health status, were initially included in 
this	prospective	cross‐sectional	study.	The	study	excluded	patients	
whose medical or dental status was not complete or who could not 
be	sex	and	age	matched	with	a	healthy	control	(Figure	1).	The	HSCT	
recipients included in this study may have received anticancer ther‐
apies using standard chemotherapy schemas even years before pro‐
ceeding to HSCT and had received conditioning chemotherapy with 
or without TBI, as previously described.6
The healthy control group was recruited from the Swiss Bone 
Marrow	 Donor	 Registry	 of	 The	 Blood	 Transfusion	 Service	 SRC	
Basel, Switzerland.22 The final study groups were formed via blinded 
matching	of	the	HSCT	recipients	with	controls	by	age	and	sex.
The	 dental	 examinations	 of	 the	 patients	 were	 carried	 out	 by	
experienced	dental	 practitioners	 in	 the	Department	of	Preventive	
Dentistry	 and	 Oral	 Microbiology,	 School	 of	 Dental	 Medicine,	
University of Basel, immediately prior to HSCT (most often a few 
days	 prior).	 A	 thorough	 clinical	 oral	 examination	 included	 a	 pan‐
oramic	 radiograph	 and	 decayed,	 missing	 and	 filled	 teeth	 (DMFT)	
index	 calculation	 according	 to	 the	 WHO.23 Acute oral infections 
were diagnosed if (a) fistula, (b) symptomatic periapical process, (c) 
symptomatic deep caries, (d) wound/ulcer or (e) acute periodontal 
abscess were observed.
Stimulated saliva flow rate (SSFR) was measured at the begin‐
ning	of	the	dental	examination	and	before	any	clinical	assessments.	
SSFR	was	 collected	 by	 chewing	 a	 neutral	 paraffin	 wax.	 An	 indi‐
vidually packed, commercially available, neutral piece of paraffin 
wax	 (0.9	g/wax;	 Orion	 Diagnostica,	 Espoo,	 Finland)	 was	 chewed	
for 1 minute while swallowing saliva. Chewing was continued for 
5 minutes, and generated saliva was collected. SSFR measurements 
of	≤0.7	mL/min	were	defined	 as	hyposalivation	 and	<0.3	mL/min	
as severe hyposalivation.17 All relevant medical data, including di‐
agnosis and conditioning‐related information, were collected from 
medical records.
To avoid bacteraemia and to shorten the time needed to perform 
dental	examinations	of	the	severely	ill	HSCT	recipients,	ongoing	or	
treated periodontitis was assessed from panoramic radiographs. 
Periodontitis	was	determined	according	to	Pepelassi	and	Diamanti‐
Kipioti,	to	be	present	if	radiological	attachment	loss	(RAL),	for	exam‐
ple, the distance between the cementoenamel junction (CEJ) and the 
alveolar bone crest was observed to be >3 mm.24
The	oral	health	of	the	healthy	control	group	was	similarly	exam‐
ined	by	the	same	dental	practitioners.	Panoramic	radiographs	were	
not taken of the healthy control group, but a detailed periodontal 
F I G U R E  1   Flow diagram showing patient selection for the study







The means and standard deviation of the oral health parameters, 
including	 SSFR,	 DMFT	 index,	 number	 of	 teeth,	 number	 of	 caries	
lesions and the frequency of periodontitis, were calculated and 
compared between allogeneic HSCT recipients and controls. The 
Pearson	Chi‐square,	t test and Mann‐Whitney U test were used to 
determine statistical significance. A P‐value <0.05 was considered 




A total of 143 of the 339 adult allogeneic HSCT recipients were 
ultimately	included	in	this	study	after	age‐	and	sex‐matching	with	
healthy controls (Figure 1). The mean age of both study groups 
(HSCT	 recipients	 and	 controls)	 was	 44.8	years	 (21‐58),	 with	 70	
male	and	73	female	subjects	per	group.	Ninety‐one	(63.6%)	of	the	
HSCT recipients had been diagnosed with their haematological 
malignancy	within	 1	year,	 40	 (28.0%)	 recipients	were	 diagnosed	
within	 1‐5	years,	 and	 12	 (8.4%)	 recipients	were	 diagnosed	more	
than 5 years before the pre‐HSCT dental check‐up. The descrip‐
tive statistics and diagnoses of the HSCT recipients are presented 
in Table 1.
3.2 | Stimulated salivary flow rates




The number of caries lesions was significantly higher in HSCT 
recipients	pre‐HSCT	 (mean	±	SD:	0.9	±	1.6)	 compared	 to	controls	
(mean	±	SD:	 0.4	±	1.0;	P	=	0.002).	 Similarly,	 the	DMFT	 index	was	
significantly higher compared with controls (P = 0.016). No statis‐




controls. The difference was not statistically significant. The mean 
RAL	of	the	HSCT	recipients	was	4.8	mm	±	SD:	2.8	mm.
3.5 | Acute infections
Acute symptomatic infections were observed in nine HSCT recipi‐
ents	(6.3%)	and	none	of	the	controls.	One	patient	had	a	fistula,	two	
patients had a symptomatic periapical process, four patients had 





caries lesions, were statistically significantly poorer in HSCT recipi‐
ents compared to the controls in the present study.
TA B L E  1  Descriptives	of	the	study	subjects
Allogeneic HSCT recipients (143)
Age
























ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; 
CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; 
MDS,	myelodysplastic	syndrome;	MH,	Hodgkin’s	lymphoma;	MPN,	my‐
eloproliferative	 neoplasm;	 NHL,	 non‐Hodgking’s	 lymphoma;	 PCD,	
plasma cell dyscrasia.
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Previous	 studies	 focusing	 on	 oral	 diseases	 of	HSCT	 recipients	
pre‐HSCT are sparse, and the results are somewhat inconsistent. 
Similar to our results, a high prevalence of oral diseases was ob‐
served	in	a	study	by	Durey	et	al	(2009),	as	93.6%	of	94	subjects	had	
some oral disease or a need for dental treatment pre‐HSCT and in 
a study by Elad et al (2003), the prevalence of decayed teeth was 
50%	and	need	 for	 scaling	 and	oral	 hygiene	 instruction	was	47.8%	
in 46 subjects pre‐HSCT.18,20 However, another study reported no 
differences in caries parameters of HSCT recipients pre‐HSCT com‐
pared with a randomly selected registry‐based population consisting 
of a similarly aged group.26 Busjan et al21 found that 39 patients with 
newly diagnosed acute leukaemia already had poorer oral health, in‐
cluding caries and periodontitis, prior to any treatments compared 
with a healthy control group. These intriguing findings suggest that 
the	 preceding	 therapies	 do	 not	 completely	 explain	 the	 poor	 oral	
health of HSCT recipients.
One	third	(36.4%)	of	the	HSCT	recipients	in	our	study	were	diag‐
nosed with their haematological malignancies over 1 year before the 
pre‐HSCT dental check‐up. Therefore, the likelihood that the pre‐
ceding anticancer therapies also affected oral health is high among 
these recipients. HSCT recipients commonly receive intensive 
conditioning chemotherapy, with or without TBI, prior to HSCT.4 
Chemotherapy and the conditioning elicit oral morbidity, particularly 
hyposalivation.6‐8,17,27 The present study is also consistent with, and 
further confirms, our previous results, in which SSFR was lower pre‐
HSCT compared to a control group.6,7,16 Saliva protects against oral 
diseases, and the hyposalivation observed in this study may mark‐
edly contribute to oral comorbidities.17
We did not have information on the dental treatment history of 
the	HSCT	 recipients	 prior	 to	 our	 examination.	 Therefore,	 the	 pa‐
tients may have had dental care, more than usual, between their 
initial	diagnosis	and	HSCT.	This	treatment	could	explain	the	differ‐
ence	 in	 DMFT	 index.	 However,	 and	 contrary	 to	 this	 assumption,	
the number of caries was higher in the HSCT recipients compared 
to the controls. One limitation of this study is that information on 
preceding dental treatments was not available. Further studies are 
needed, particularly to investigate whether hyposalivation is already 
more common in patients with haematological disorders at the time 
of diagnosis.
Poor	 oral	 health,	 especially	 periodontitis	 and	 tooth	 loss,	 was	
linked to several systemic diseases, cancers and increased mortal‐
ity.9‐12,15 However, there is little evidence suggesting poor oral health 
as a risk factor for haematological malignancies.14,15 The influence of 
periodontitis and other oral infections on treatment outcomes and 
oral and systemic morbidity in haematological malignancies was sug‐
gested already decades ago.28‐32 However, some studies of particu‐
lar chronic oral infections found not association with severe systemic 
complications post‐HSCT.33,34 Therefore, the effects of periodon‐
titis and poor oral health on treatment outcomes and oral comor‐
bidity post‐HSCT are not clear and warrant further study. However, 
periodontal diseases are, at least, common in HSCT recipients.18,19,35 
Our results on periodontitis are consistent with previous studies, as 
in the current study, a high prevalence of periodontitis, in terms of 
RAL	>3	mm,	was	observed	in	53.8%	of	these	HSCT	recipients.18,19,35 
Periodontitis	was	slightly	more	prevalent	 in	HSCT	recipients	com‐
pared with the controls, but the result was not statistically signif‐
icant. Owing to different measurement methods for the presence 
of periodontitis between HSCT recipients and controls, comparison 
must	be	treated	with	caution.	Our	examinations	could	not	include	all	
of the necessary oral parameters to assess periodontal and gingival 
diseases and oral hygiene due to the often poor health conditions, 
immunosuppression	 and	 time	 limitations.	 Periodontitis	 in	 HSCT	
recipients was determined via measuring radiological attachment 
loss from panoramic radiographs, and periodontitis in the controls 
was determined via measuring clinical attachment loss and probing 
pocket	depth.	According	 to	 the	 recommendation	by	Pepelassi	and	
Diamanti‐Kipioti,	the	bone	level	in	panoramic	radiographs	was	con‐
sidered to be normal if the distance between CEJ and AC was up 
to 3 mm. Therefore, alveolar bone was considered lost, indicating 
periodontitis, if the CEJ‐AC distance was >3 mm.24 This RAL‐based 
method was used for HSCT recipients, as in our previous study, to 
avoid bacteraemia and to keep the dental visits short, because these 
visits occurred just prior to transplantation.26 This method may 
cause inaccuracies in the diagnosis of periodontitis, and it is possible 
Mean (±SD) Yes (%) No (%) P‐value
Allogeneic HSCT recipients
DMFT	index 16.8	(7.2) 0.016
Number of teeth 26.2	(5.7) 0.222
Number of caries 
lesion
0.9 (1.6) 0.002
Periodontitis	(n;	%) 77	(53.8) 66 (46.2) 0.408
Controls
DMFT	index 14.7	(6.5)
Number of teeth 27.8	(2.5)




TA B L E  2  Comparisons	of	DMFT	index,	
number of teeth, number of caries lesions, 
and presence of periodontitis between 
HSCT recipients and controls
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that early signs of periodontal disease and gingivitis were not no‐
ticed.24,36 Furthermore, information on the activity of periodontal 
disease or past treatment of periodontitis could not be obtained 
with this method. This limitation should be considered a weakness 
of the methodology, but this method was chosen to avoid harming 
the HSCT recipients.
The HSCT recipients were compared with a healthy control group 
that	 was	 recruited	 from	 the	 Swiss	 Bone	Marrow	Donor	 Registry.	
Bone marrow donors are often relatives of HSCT recipients, and 
the	controls	were	age‐	and	sex‐matched	with	the	recipients	to	en‐
hance the comparability even further. In the limits of this study, oral 
health habits or lifestyle‐related confounders were not available and 
could not be adjusted for in this study. However, the prevalence of 
smoking was somewhat lower among HSCT recipients compared 
with	the	controls	(36%	vs	41%).	Due	to	the	narrow	age	distribution	
(26‐58 years) and female prevalence in the controls, the oldest HSCT 
recipients	were	excluded	from	the	study	(Figure	1).	Younger	subjects	
generally have fewer medications and other illnesses, and this re‐
moves some of the most relevant confounders and makes the study 
groups highly comparable. Further studies, with longitudinal follow‐
up, on the associations of biochemical, social and behavioural factors 
with oral health in HSCT recipients are warranted.
In	conclusion,	oral	examinations	pre‐HSCT	showed	a	high	prev‐
alence of oral disorders in HSCT recipients. These findings support 
the recommendations for an early dental check‐up prior to HSCT 
to eliminate acute infection foci, prepare HSCT recipients, and, 
if possible, investigate the effects of oral disorders on post‐HSCT 
complications.29,37
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